S 1097
Advanced toward a vote
Establishes an interagency task force between the Patent and Trademark Office and the Food and Drug Administration to share information and coordinate on patents for human drugs and biological products.
Official title: Interagency Patent Coordination and Improvement Act of 2025
Timeline each lane is a chamber; dates pull from congress.gov actions
Senate
Introduced
24-MAR-2025
Referred
24-MAR-2025
Approved by committee
03-APR-2025
Reported
10-APR-2025
On the calendar
10-APR-2025
- Establishes the Interagency Task Force on Patents, with members appointed by the USPTO Director and the FDA Commissioner.
- Requires the two agencies to enter into or update a memorandum of understanding to carry out the task force's duties.
- Requires the task force to set confidentiality protocols, including 30 days' notice to drug sponsors before their information is shared.
- Requires the USPTO Director to report to the Judiciary Committees within 4 years on how the shared FDA information is used in patent examinations.
Covers an older version. The newest CRS summary describes the bill as of "Introduced in Senate" (24-MAR-2025); the text has changed since (Reported to Senate, 10-APR-2025).
CRS is the Library of Congress's nonpartisan research office. Read it on congress.gov- Judiciary Committee (Senate)
Commerce
■ 2 R■ 2 D
2 Democrats
2 Republicans